Safety Profile of Tolvaptan in the Treatment of Autosomal Dominant Polycystic Kidney Disease
出版年份 2021 全文链接
标题
Safety Profile of Tolvaptan in the Treatment of Autosomal Dominant Polycystic Kidney Disease
作者
关键词
-
出版物
Therapeutics and Clinical Risk Management
Volume Volume 17, Issue -, Pages 649-656
出版商
Informa UK Limited
发表日期
2021-06-29
DOI
10.2147/tcrm.s286952
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Sodium and urea excretion as determinants of urine output in autosomal dominant polycystic kidney disease patients on V2 receptor antagonists: impact of dietary intervention
- (2020) Gabrielle Côté et al. INTERNATIONAL UROLOGY AND NEPHROLOGY
- Comparison of the Hepatotoxic Potential of Two Treatments for Autosomal-Dominant Polycystic Kidney DiseaseUsing Quantitative Systems Toxicology Modeling
- (2020) J. L. Woodhead et al. PHARMACEUTICAL RESEARCH
- Autosomal-dominant polycystic kidney disease: tolvaptan use in adolescents and young adults with rapid progression
- (2020) Rupesh Raina et al. PEDIATRIC RESEARCH
- Urinary Lithogenic Risk Profile in ADPKD Patients Treated with Tolvaptan
- (2020) Matteo Bargagli et al. Clinical Journal of the American Society of Nephrology
- Quantitative Systems Toxicology Modeling Predicts that Reduced Biliary Efflux Contributes to Tolvaptan Hepatotoxicity
- (2020) James J. Beaudoin et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Case report: tolvaptan-associated creatine kinase elevation in two patients with autosomal dominant polycystic kidney disease (ADPKD)
- (2020) I. Agraz-Pamplona et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- The NOCTURNE Randomized Trial Comparing 2 Tolvaptan Formulations
- (2020) Ronald D. Perrone et al. Kidney International Reports
- Tolvaptan add‐on therapy in patients with acute heart failure: A systematic review and meta‐analysis
- (2020) Xiandu Luo et al. Pharmacology Research & Perspectives
- Tolvaptan- and Tolvaptan-Metabolite-Responsive T Cells in Patients with Drug-Induced Liver Injury
- (2020) Andrew Gibson et al. CHEMICAL RESEARCH IN TOXICOLOGY
- Markers of endothelial dysfunction and arterial stiffness in patients with early‐stage autosomal dominant polycystic kidney disease: A meta‐analysis
- (2020) Ioannis Bellos et al. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- Multicenter Study of Long-Term Safety of Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease
- (2020) Vicente E. Torres et al. Clinical Journal of the American Society of Nephrology
- Tolvaptan: A Review in Autosomal Dominant Polycystic Kidney Disease
- (2019) Hannah A. Blair DRUGS
- Octreotide-LAR in later-stage autosomal dominant polycystic kidney disease (ALADIN 2): A randomized, double-blind, placebo-controlled, multicenter trial
- (2019) Norberto Perico et al. PLOS MEDICINE
- Altered Expression and Function of Hepatic Transporters in a Rodent Model of Polycystic Kidney Disease
- (2019) Jacqueline Bezençon et al. DRUG METABOLISM AND DISPOSITION
- Autosomal dominant polycystic kidney disease: updated perspectives
- (2019) Anjay Rastogi et al. Therapeutics and Clinical Risk Management
- Tolvaptan Response Improves Overall Survival in Patients with Refractory Ascites: A Meta-Analysis
- (2019) Ioannis Bellos et al. DIGESTIVE DISEASES
- Idiosyncratic hepatic toxicity in autosomal dominant polycystic kidney disease (ADPKD) patient in combined treatment with tolvaptan and amoxicillin/clavulanic acid: a case report
- (2019) Angela Maria Pellegrino et al. BMC Nephrology
- Epidemiology of Autosomal Dominant Polycystic Kidney Disease in Olmsted County
- (2019) Tatsuya Suwabe et al. Clinical Journal of the American Society of Nephrology
- Elevation of the serum liver enzyme levels during tolvaptan treatment in patients with autosomal dominant polycystic kidney disease (ADPKD)
- (2018) Shiho Makabe et al. Clinical and Experimental Nephrology
- Semaphorin 7A in circulating regulatory T cells is increased in autosomal-dominant polycystic kidney disease and decreases with tolvaptan treatment
- (2018) Yashang Lee et al. Clinical and Experimental Nephrology
- Long-Term Administration of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease
- (2018) Marie E. Edwards et al. Clinical Journal of the American Society of Nephrology
- Tolvaptan for Heart Failure in Chronic Kidney Disease Patients: A Systematic Review and Meta-Analysis
- (2018) Jonathan Sen et al. Heart Lung and Circulation
- Determinants of Urine Volume in ADPKD Patients Using the Vasopressin V2 Receptor Antagonist Tolvaptan
- (2018) Bart J. Kramers et al. AMERICAN JOURNAL OF KIDNEY DISEASES
- Altered Hepatobiliary Disposition of Tolvaptan and Selected Tolvaptan Metabolites in a Rodent Model of Polycystic Kidney Disease
- (2018) James J. Beaudoin et al. DRUG METABOLISM AND DISPOSITION
- Effect of Lanreotide on Kidney Function in Patients With Autosomal Dominant Polycystic Kidney Disease
- (2018) Esther Meijer et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- The Role of Tolvaptan Administration After Cardiac Surgery: A Meta-Analysis
- (2018) Ioannis Bellos et al. JOURNAL OF CARDIOTHORACIC AND VASCULAR ANESTHESIA
- Polycystic kidney disease
- (2018) Carsten Bergmann et al. Nature Reviews Disease Primers
- Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: the TEMPO 4:4 Trial
- (2017) Vicente E Torres et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease
- (2017) Vicente E. Torres et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tolvaptan treatment for severe neonatal autosomal-dominant polycystic kidney disease
- (2017) Rodney D. Gilbert et al. PEDIATRIC NEPHROLOGY
- Candidate Risk Factors and Mechanisms for Tolvaptan-Induced Liver Injury Are Identified Using a Collaborative Cross Approach
- (2017) Merrie Mosedale et al. TOXICOLOGICAL SCIENCES
- The effect of disease severity markers on quality of life in autosomal dominant polycystic kidney disease: a systematic review, meta-analysis and meta-regression
- (2017) Myrte K. Neijenhuis et al. BMC Nephrology
- Polyuria due to vasopressin V2 receptor antagonism is not associated with increased ureter diameter in ADPKD patients
- (2016) Niek F. Casteleijn et al. Clinical and Experimental Nephrology
- The Efficacy and Safety of Tolvaptan in Patients with Hyponatremia: A Meta-Analysis of Randomized Controlled Trials
- (2016) Benlei Li et al. CLINICAL DRUG INVESTIGATION
- Clinical Pattern of Tolvaptan-Associated Liver Injury in Subjects with Autosomal Dominant Polycystic Kidney Disease: Analysis of Clinical Trials Database
- (2015) Paul B. Watkins et al. DRUG SAFETY
- Autosomal-dominant polycystic kidney disease (ADPKD): executive summary from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference
- (2015) Arlene B. Chapman et al. KIDNEY INTERNATIONAL
- Inhibition of Human Hepatic Bile Acid Transporters by Tolvaptan and Metabolites: Contributing Factors to Drug-Induced Liver Injury?
- (2015) Jason R. Slizgi et al. TOXICOLOGICAL SCIENCES
- Review of Tolvaptan’s Pharmacokinetic and Pharmacodynamic Properties and Drug Interactions
- (2014) Purav Bhatt et al. Journal of Clinical Medicine
- Everolimus does not further reduce polycystic liver volume when added to long acting octreotide: Results from a randomized controlled trial
- (2013) Melissa Chrispijn et al. JOURNAL OF HEPATOLOGY
- Effect of longacting somatostatin analogue on kidney and cyst growth in autosomal dominant polycystic kidney disease (ALADIN): a randomised, placebo-controlled, multicentre trial
- (2013) Anna Caroli et al. LANCET
- Tolvaptan in Patients with Autosomal Dominant Polycystic Kidney Disease
- (2012) Vicente E. Torres et al. NEW ENGLAND JOURNAL OF MEDICINE
- Everolimus in Patients with Autosomal Dominant Polycystic Kidney Disease
- (2010) Gerd Walz et al. NEW ENGLAND JOURNAL OF MEDICINE
- Vasopressin Directly Regulates Cyst Growth in Polycystic Kidney Disease
- (2007) X. Wang et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now